DOTA Conjugated JM#21 derivative 7
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney. DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
For research use only. We do not sell to patients.
- CAS No.: 3033865-40-3
- Formula: C66H114N22O16
- Molecular Weight:1471.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
|
RDC Peptide |
Chemical Information
-
CAS No. 3033865-40-3
-
Molecular Weight 1471.75
-
Formula C66H114N22O16
-
Sequence
{d-Ile}-LRWSRK-Lys(DOTA)-NH2
-
Sequence Shortening
{d-Ile}-Leu-Arg-Trp-Ser-Arg-Lys-Lys(DOTA)-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)